Mechanisms maintaining antibody-induced enhancement of allografts. II. Mediation of specific suppression by short lived CD4+ T cells.
In DA rats grafted with PVG hearts, the injection of 1 ml of Wistar-Furth x DA)F1 anti-PVG serum on the day of grafting prevents rejection and induces a state of specific unresponsiveness. An adoptive transfer assay was used to test the capacity of T cell subsets, taken from rats given enhancing serum, to either restore rejection or to transfer unresponsiveness to syngeneic hosts irradiated with 9 Gy and grafted with donor (PVG) or third party (Wistar-Furth) hearts. W3/25+ (CD4+) cells from these animals retained some capacity to restore rejection until 50 days posttransplant, after which they invariably failed to restore PVG graft rejection but retained the capacity to effect Wistar-Furth rejection. At this time CD4+ cells were also capable of inhibiting naive but not specifically sensitized CD4+ cells capacity to restore PVG graft rejection in irradiated hosts. The development of CD4+ suppressor cells was concurrent with the appearance of clinically evident unresponsiveness in the host. MRC Ox8+ (CD8+) cells from enhanced rats when mixed with naive CD4+ cells delayed rejection in adoptive recipients but did not reestablish unresponsiveness. Paradoxically, the CD4+ cells that transfer unresponsiveness to the adoptive host proliferate such as normal cells in MLC to both donor and third party alloantigen. Unfractionated cells, CD4+ or CD8+ cells did not proliferate to relevant idiotype in vitro. The CD4+ cells after 3 days in culture, with either alloantigen or idiotype-bearing stimulator cells, lost their capacity to suppress in the adoptive transfer assay. The maintenance of specific unresponsiveness was thus shown to be due to a CD4+ suppressor T cell whose function was lost in culture, and therefore could not be detected in MLC or idiotype assays.
Pearce
N W
NW
Department of Renal Medicine, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.
Spinelli
A
A
Gurley
K E
KE
Dorsch
S E
SE
Hall
B M
BM
D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000818:Animals; D000945:Antigens, Differentiation, T-Lymphocyte; D016827:CD8 Antigens; D002470:Cell Survival; D002478:Cells, Cultured; D000939:Epitopes / Q000276:immunology; D005260:Female; D006082:Graft Enhancement, Immunologic / Q000379:methods; D006085:Graft Survival / Q000528:radiation effects; D016027:Heart Transplantation; D007106:Immune Sera / Q000008:administration & dosage*; D007108:Immune Tolerance; D007116:Immunization, Passive; D007130:Immunoglobulin Idiotypes / Q000276:immunology; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D008213:Lymphocyte Activation; D007959:Lymphocyte Culture Test, Mixed; D008297:Male; D010641:Phenotype; D051381:Rats; D011920:Rats, Inbred WF; D050378:T-Lymphocytes, Regulatory / Q000276:immunology / Q000502:physiology / Q000637:transplantation*
D000276:Adjuvants, Immunologic; D000945:Antigens, Differentiation, T-Lymphocyte; D016827:CD8 Antigens; D000939:Epitopes; D007106:Immune Sera; D007130:Immunoglobulin Idiotypes; D007166:Immunosuppressive Agents